دورية أكاديمية
Twelve‐month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed‐loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
| العنوان: | Twelve‐month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed‐loop therapy outcomes versus conventional therapy in adults with type 1 diabetes. |
|---|---|
| المؤلفون: | Edd, Shannon N., Castañeda, Javier, Choudhary, Pratik, Kolassa, Ralf, Keuthage, Winfried, Kroeger, Jens, Thivolet, Charles, Evans, Mark, Ré, Roseline, Cellot, Jessica, de Portu, Simona, Vorrink, Linda, Shin, John, van den Heuvel, Tim, Cohen, Ohad, Reznik, Yves, Catargi, Bogdan, Kessler, Laurence, Borot, Sophie, Schaepelynck‐Belicar, Pauline |
| المصدر: | Diabetes, Obesity & Metabolism; Nov2023, Vol. 25 Issue 11, p3212-3222, 11p |
| مصطلحات موضوعية: | TYPE 1 diabetes, INSULIN aspart, RANDOMIZED controlled trials, GLYCOSYLATED hemoglobin, HYPOGLYCEMIA, PATIENT reported outcome measures |
| مستخلص: | Aims: To reassess the 6‐month efficacy and to assess the 12‐month sustained efficacy of the MiniMed™ 780G advanced hybrid closed‐loop automated insulin delivery (AID) system compared to multiple daily injections plus intermittently scanned glucose monitoring (MDI+isCGM) in people with type 1 diabetes not meeting glucose targets. Methods: The ADAPT study was a prospective, multicentre, open‐label, randomized control trial in people with type 1 diabetes, with a glycated haemoglobin (HbA1c) concentration of at least 8.0% (64 mmol/mol), on MDI+isCGM therapy. After a 6‐month study phase, participants randomized at baseline to MDI+isCGM switched to AID (SWITCH) while the others continued AID therapy (SUSTAIN) for an additional 6 months. The primary endpoint of this continuation phase was the within‐group change in mean HbA1c between 6 and 12 months, with superiority in the SWITCH group and noninferiority in the SUSTAIN group (ClinicalTrials.gov: NCT04235504). Results: A total of 39 SWITCH and 36 SUSTAIN participants entered the continuation phase. In the SWITCH group, HbA1c was significantly decreased by −1.4% (95% confidence interval [CI] −1.7% to −1.1%; P < 0.001) from a mean ± SD of 8.9% ± 0.8% (73.9 ± 8.6 mmol/mol) at 6 months to 7.5% ± 0.6% (58.5 ± 6.9 mmol/mol) at 12 months. Mean HbA1c increased by 0.1% (95% CI −0.05% to +0.25%), from 7.3% ± 0.6% (56.5 ± 6.7 mmol/mol) to 7.4% ± 0.8% (57.7 ± 9.1 mmol/mol) in the SUSTAIN group, meeting noninferiority criteria. Three severe hypoglycaemia events occurred in two SWITCH participants during the continuation phase. Conclusion: ADAPT study phase glycaemic improvements were reproduced and sustained in the continuation phase, supporting the early adoption of AID therapy in people with type 1 diabetes not meeting glucose targets on MDI therapy. [ABSTRACT FROM AUTHOR] |
| Copyright of Diabetes, Obesity & Metabolism is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| قاعدة البيانات: | Complementary Index |
| ResultId |
1 |
|---|---|
| Header |
edb Complementary Index 172756252 1040 6 Academic Journal academicJournal 1040.240234375 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=172756252&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Twelve‐month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed‐loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Edd%2C+Shannon+N%2E%22">Edd, Shannon N.</searchLink><br /><searchLink fieldCode="AR" term="%22Castañeda%2C+Javier%22">Castañeda, Javier</searchLink><br /><searchLink fieldCode="AR" term="%22Choudhary%2C+Pratik%22">Choudhary, Pratik</searchLink><br /><searchLink fieldCode="AR" term="%22Kolassa%2C+Ralf%22">Kolassa, Ralf</searchLink><br /><searchLink fieldCode="AR" term="%22Keuthage%2C+Winfried%22">Keuthage, Winfried</searchLink><br /><searchLink fieldCode="AR" term="%22Kroeger%2C+Jens%22">Kroeger, Jens</searchLink><br /><searchLink fieldCode="AR" term="%22Thivolet%2C+Charles%22">Thivolet, Charles</searchLink><br /><searchLink fieldCode="AR" term="%22Evans%2C+Mark%22">Evans, Mark</searchLink><br /><searchLink fieldCode="AR" term="%22Ré%2C+Roseline%22">Ré, Roseline</searchLink><br /><searchLink fieldCode="AR" term="%22Cellot%2C+Jessica%22">Cellot, Jessica</searchLink><br /><searchLink fieldCode="AR" term="%22de+Portu%2C+Simona%22">de Portu, Simona</searchLink><br /><searchLink fieldCode="AR" term="%22Vorrink%2C+Linda%22">Vorrink, Linda</searchLink><br /><searchLink fieldCode="AR" term="%22Shin%2C+John%22">Shin, John</searchLink><br /><searchLink fieldCode="AR" term="%22van+den+Heuvel%2C+Tim%22">van den Heuvel, Tim</searchLink><br /><searchLink fieldCode="AR" term="%22Cohen%2C+Ohad%22">Cohen, Ohad</searchLink><br /><searchLink fieldCode="AR" term="%22Reznik%2C+Yves%22">Reznik, Yves</searchLink><br /><searchLink fieldCode="AR" term="%22Catargi%2C+Bogdan%22">Catargi, Bogdan</searchLink><br /><searchLink fieldCode="AR" term="%22Kessler%2C+Laurence%22">Kessler, Laurence</searchLink><br /><searchLink fieldCode="AR" term="%22Borot%2C+Sophie%22">Borot, Sophie</searchLink><br /><searchLink fieldCode="AR" term="%22Schaepelynck‐Belicar%2C+Pauline%22">Schaepelynck‐Belicar, Pauline</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Diabetes, Obesity & Metabolism; Nov2023, Vol. 25 Issue 11, p3212-3222, 11p ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22TYPE+1+diabetes%22">TYPE 1 diabetes</searchLink><br /><searchLink fieldCode="DE" term="%22INSULIN+aspart%22">INSULIN aspart</searchLink><br /><searchLink fieldCode="DE" term="%22RANDOMIZED+controlled+trials%22">RANDOMIZED controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22GLYCOSYLATED+hemoglobin%22">GLYCOSYLATED hemoglobin</searchLink><br /><searchLink fieldCode="DE" term="%22HYPOGLYCEMIA%22">HYPOGLYCEMIA</searchLink><br /><searchLink fieldCode="DE" term="%22PATIENT+reported+outcome+measures%22">PATIENT reported outcome measures</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Aims: To reassess the 6‐month efficacy and to assess the 12‐month sustained efficacy of the MiniMed™ 780G advanced hybrid closed‐loop automated insulin delivery (AID) system compared to multiple daily injections plus intermittently scanned glucose monitoring (MDI+isCGM) in people with type 1 diabetes not meeting glucose targets. Methods: The ADAPT study was a prospective, multicentre, open‐label, randomized control trial in people with type 1 diabetes, with a glycated haemoglobin (HbA1c) concentration of at least 8.0% (64 mmol/mol), on MDI+isCGM therapy. After a 6‐month study phase, participants randomized at baseline to MDI+isCGM switched to AID (SWITCH) while the others continued AID therapy (SUSTAIN) for an additional 6 months. The primary endpoint of this continuation phase was the within‐group change in mean HbA1c between 6 and 12 months, with superiority in the SWITCH group and noninferiority in the SUSTAIN group (ClinicalTrials.gov: NCT04235504). Results: A total of 39 SWITCH and 36 SUSTAIN participants entered the continuation phase. In the SWITCH group, HbA1c was significantly decreased by −1.4% (95% confidence interval [CI] −1.7% to −1.1%; P < 0.001) from a mean ± SD of 8.9% ± 0.8% (73.9 ± 8.6 mmol/mol) at 6 months to 7.5% ± 0.6% (58.5 ± 6.9 mmol/mol) at 12 months. Mean HbA1c increased by 0.1% (95% CI −0.05% to +0.25%), from 7.3% ± 0.6% (56.5 ± 6.7 mmol/mol) to 7.4% ± 0.8% (57.7 ± 9.1 mmol/mol) in the SUSTAIN group, meeting noninferiority criteria. Three severe hypoglycaemia events occurred in two SWITCH participants during the continuation phase. Conclusion: ADAPT study phase glycaemic improvements were reproduced and sustained in the continuation phase, supporting the early adoption of AID therapy in people with type 1 diabetes not meeting glucose targets on MDI therapy. [ABSTRACT FROM AUTHOR] ) Array ( [Name] => Abstract [Label] => [Group] => Ab [Data] => <i>Copyright of Diabetes, Obesity & Metabolism is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1111/dom.15217
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 11
[StartPage] => 3212
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => TYPE 1 diabetes
[Type] => general
)
[1] => Array
(
[SubjectFull] => INSULIN aspart
[Type] => general
)
[2] => Array
(
[SubjectFull] => RANDOMIZED controlled trials
[Type] => general
)
[3] => Array
(
[SubjectFull] => GLYCOSYLATED hemoglobin
[Type] => general
)
[4] => Array
(
[SubjectFull] => HYPOGLYCEMIA
[Type] => general
)
[5] => Array
(
[SubjectFull] => PATIENT reported outcome measures
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Twelve‐month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed‐loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Edd, Shannon N.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Castañeda, Javier
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Choudhary, Pratik
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kolassa, Ralf
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Keuthage, Winfried
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kroeger, Jens
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Thivolet, Charles
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Evans, Mark
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ré, Roseline
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cellot, Jessica
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => de Portu, Simona
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vorrink, Linda
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shin, John
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => van den Heuvel, Tim
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cohen, Ohad
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Reznik, Yves
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Catargi, Bogdan
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kessler, Laurence
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Borot, Sophie
)
)
)
[19] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Schaepelynck‐Belicar, Pauline
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 11
[Text] => Nov2023
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 14628902
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 25
)
[1] => Array
(
[Type] => issue
[Value] => 11
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Diabetes, Obesity & Metabolism
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |